T1	p 130 136	of the
T2	p 150 162	and throat ]
T3	p 353 380	98 patients aged between 18
T4	p 385 439	75 suffering from pain-inflammatory pathologies of ENT
T5	i 59 69	nimesulide
T6	i 73 84	suppository
T7	i 143 147	nose
T8	i 200 218	new pharmaceutical
T9	i 268 278	Nimesulide
T10	i 335 349	flurbiprofen ,
T11	i 492 503	suppository
T12	i 577 588	antipyretic
T13	i 804 805	.
T14	o 30 38	efficacy
T15	o 46 55	tolerance
T16	o 148 149	,
T17	o 154 162	throat ]
T18	o 169 194	efficacy and tolerability
T19	o 231 242	non-steroid
T20	o 536 597	marked anti-inflammatory , analgesic and antipyretic activity
T21	o 627 650	progressive improvement
T22	o 713 731	complete remission
T23	o 763 803	speed and duration of therapeutic action
T24	o 824 854	effectiveness and tolerability
T25	o 900 907	patient